Pricing Log in Create free account
Saturday 17 October 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Charles River Laboratories International, Inc. (CRL) Debt to equity

Alert me on Debt to equity

Charles River Laboratories International, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.9×, up 0.2× from fiscal 2025 (0.7×). Over the past ten years it has ranged from 0.6× (fiscal 2024) to 1.5× (fiscal 2016); the current reading is higher than 18% of that period. That is above the Diagnostics & Research industry median of 0.1× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.7× 4.29%
FY2024 0.6× (12.07%)
FY2023 0.7× (19.08%)
FY2022 0.9× (13.43%)
FY2021 1.0× 12.24%
FY2020 0.9× (18.93%)
FY2019 1.2× (8.78%)
FY2018 1.3× 15.60%
FY2017 1.1× (25.72%)
FY2016 1.5× 25.78%

Quarterly newest first

Period Debt to equity Change
Jun 2026 0.9× 1.85%
Mar 2026 0.9× 34.13%
Dec 2025 0.7× 5.17%
Sep 2025 0.6× (7.69%)
42 more quarters

Against its own ten years

Low 0.6× High 1.5×
Ten-year median 1.0×
Current reading's percentile 18

Debt to equity against peers

Company Debt to equity
GH Guardant Health, Inc. compare −6.7×
MEDP Medpace Holdings, Inc. compare 0.0×
TWST Twist Bioscience Corporation compare 0.0×
ICLR ICON PLC compare 0.4×
RVTY Revvity Inc. compare 0.4×
QGEN QIAGEN N.V. compare 0.5×
LH Labcorp Holdings Inc. compare 0.7×
DGX Quest Diagnostics Incorporated compare 0.7×
CRL Charles River Laboratories International, Inc. 0.9×
Diagnostics & Research industry median 0.1×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on CRL